Trial intelligence / Profile preview

Prospective serum MALDI-TOF MS proteomic profiling in glioblastoma treated with standard therapy

2009-013662-33Phase 2Completed

Sponsor: Fondazione Centro San Raffaele
Start: Oct 2009
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Fondazione Centro San Raffaele. Primary endpoint: Correlation between proteomic profile and outcome. Started Oct 2009; status: completed.

Drugs

temozolomide

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2009-013662-33.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-013662-33.